Session Chair Profile
As an accredited surgeon and proven leader in the biopharmaceutical industry, Clive brings a medical, academic and strong research and development perspective to Inivata, ensuring that the Inivata product line is directed to maximize potential patient benefit. He worked for over a decade in various key roles at AstraZeneca, where he oversaw R&D and medical affairs projects and groups on a global scale, was involved in R&D strategy, investor relations, and most recently led the major transformation of AstraZeneca’s UK strategic R&D sites and global HQ. Clive has extensive experience across all phases of drug development including seven marketed or close-to- market oncology products. He was also the founding Chief Executive of Health Innovation Manchester, an initiative to develop an innovation ecosystem combining industrial and academic sectors with the decentralization of £6bn per annum of health and social care services. He’s accredited as a Pharmaceutical Medicine specialist by the UK Royal College of Physicians, as well as holding an Executive MBA and Honorary Professorship of Translational Medicine at the University of Manchester.
The Future of ctDNA
What are some of the exciting areas in MRD, monitoring, stratification, etc. How can ctDNA transform cancer management?
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Recent technological advances have ushered in a new generation of non-invasive molecular applications making it feasible to reliably detect and quantify circulating tumor DNA (ctDNA). This session will review the current technologies being employed, discuss clinical applications of ctDNA and provide examples of using both quantitative and qualitative assessment of ctDNA in the clinical setting.